


Supplemental Table 1.	Effects of reduction in E3
ubiquitin ligases on signa	aling by the IL-36R.

siRNA	IL-6 (fold)	siRNA	IL-6 (fold)
Mock	5.54 ± 0.26*	PHF6	4.04 ± 0.07
Nonspecific	5.79 ± 0.06	PHF5A	8.20 ± 0.23
ANKIB1	6.28 ± 0.23	PHF7	6.05 ± 0.48
BAHD1	3.89 ± 0.32	PHF20	2.57 ± 0.07
BIRC3	3.97 ± 0.21	PHF20L1	3.19 ± 0.21
BMI1	4.98 ± 0.09	PHF21A	3.11 ± 0.22
CBL	6.12 ± 0.24	RBCK1	4.82 ± 0.09
CHD5	3.09 ± 0.02	RFWD2	2.53 ± 0.04
HRC	4.49 ± 0.04	RLIM	3.91 ± 0.10
INTS12	5.45 ± 0.17	RNF5	1.78 ± 0.07
JHDM1D	3.69 ± 0.20	RNF7	5.33 ± 0.17
KDM5B	6.29 ±0.44	RNF32	15.34 ± 0.33
LOC644006	6.44 ± 0.39	RNF39	3.83 ± 0.10
MDM2	2.09 ± 0.04	RNF114	5.44 ± 0.28
MARCH4	3.46 ± 0.17	RNF122	2.98 ± 0.19
MARCH8	7.41 ± 0.19	RNF123	12.64 ± 0.14
MEX3A	8.85 ± 0.14	RNF125	1.24 ± 0.08
MEX3D	7.28 ± 0.37	RNF133	1.84 ± 0.09
MGRN1	5.36 ± 0.20	RNF135	8.64 ± 0.59
MID2	6.42 ± 0.33	RNF152	2.11 ± 0.20
MLLT6	8.42 ± 0.82	RNF180	1.57 ± 0.03
MIB2	5.06 ± 0.10	RNF185	5.26 ± 0.52
MYCBP2	3.74 ± 0.32	TRAF6	1.03 ± 0.31
PCGF1	7.07 ± 0.49	TRIM39	6.07± 0.12
PDZRN3	5.00 ± 0.39	TRIM60	6.27 ± 0.56
PRPF19	5.65 ± 0.38	ZFAND6	2.07 ± 0.05


*Fold change was calculated by dividing the IL-6 concentration of IL-6 produced in cells induced with IL- 36γ from mock-treated cells. Each result represents mean and one standard error from three independent assays.








Supplementary Fig. 2. Ubiquitin ligase RNF125 expression is reduced in disease tissue with elevated expression of IL-36R and its agonist cytokines. **A**) Expression levels of the RNF125 are decreased in disease tissues that overexpress the IL-36R or cytokines that can induce IL-36R signaling. The data was from Boehringer Ingelheim collection of patient samples. **B**) RNA sequencing also reveals that RNF125 is inversely related to the expression of IL-1Rrp2 and the IL-36 cytokines in non-lesional and lesional skin. All differences have p values of < 0.01.



Supplemental Fig. 3. Knockdown of RNF125 inhibits the intracellular translocation of agonist-activated IL-1Rrp2. The epinuclear locations of the IL-36R have been previously demonstrated to be LAMP1+ lysosomes. Knockdown of RNF125 used a mixture of 4 siRNAs and reduced the level of RNF125 protein to 30%. DNA has been stained with DAPI. IL-1Rrp2 was stained with a specific antibody and a secondary antibody labeled with Alexa Fluor 594.



Supplementary Fig. 4. HEK293T cells expressing IL-36R contains a variety of ubiquitinations. **A**) Schematic of the protocol used to examine the types of ubiquitination on recombinant IL-1Rrp2 proteins. **B**) Western blot of the effects of de-ubiquitinases on polyubiquitinated IL-1Rrp2.